ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Contemporary Desensitization with Low Dose Rituximab Ensures Kidney Transplant Outcome beyond ABO Blood Type Incompatibility:A Comparison between past Regimens in Single Institute

H. Harada, Y. Wada, A. Mitsuke, T. Hirose, N. Fukuzawa, T. Seki.

Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan.

Meeting: 2018 American Transplant Congress

Abstract number: A154

Keywords: Antibodies, Immunosuppression, Kidney transplantation, Plasmapheresis

Session Information

Session Name: Poster Session A: Kidney Immunosuppression: Desensitization

Session Type: Poster Session

Date: Saturday, June 2, 2018

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall 4EF

INTRODUCTION: An ABO incompatible kidney transplant (ABOiKT) requires desensitization (DS). The ways of DS have been changed chronologically and the outcome could have been subsequently improved. Here we compared the outcome of ABOiKT in our institute according to the types of regimens.

METHODS: 131 ABOiKT since 1994 to 2016 were enrolled. They were divided into 4 categories according to DS. In Era I (n=18), preoperative immunosuppressants (IS) comprising CSA/AZA/CS were administered on D-3. In Era II (n=7), IS (TAC/MMF/CS) were initiated from D-14 and basiliximab (BSX) was administered. In Era III (n=53), IS (TAC/MMF/CS/BSX) were administered as in Era II. In Era IV (n=53), everolimus (EVR) was added from the beginning of IS (TAC/MMF/CS/BSX) initiation and CS were discontinued on Day 4 in some cases. Simultaneous splenectomy was done in Era I and II. Recipients in Era II to IV accepted low dose rituximab (RIT) (50mg/m2 to 200mg/body). Plasmapheresis (PP) was performed from 2 to 4 sessions according to the strength of anti-blood type antibodies (ABA) in most of patients. However, patients whose initial ABA within 16x were encouraged to spare PP in Era IV.

RESULTS: 3 out of 131 patients lost their grafts within 2 weeks due to acute antibody mediated rejection (AMR) (2 in Era I, 1 in Era III). Another patient in Era I exhibited severe HUS caused by AMR and ceased the function. Interestingly, the positivity of complement deposition (C3 or C4d) of 1H graft biopsy was higher in Era I compared to that in Era II-IV (6/18 vs. 10/106, p=0.0131). More interestingly, the half of positive cases in Era I developed AMR but none in those in ERA II-IV. Graft survivals are improving Era by Era (p=0.0157).

CONCLUSION: The outcome of contemporary ABOiKT using low dose RIT is excellent even without splenectomy with certain suppression of humoral immunity. Among them, additional RIT could bring equivalent or more excellent outcome without excessive PP in some cases. The longer follow-up should be warranted.

CITATION INFORMATION: Harada H., Wada Y., Mitsuke A., Hirose T., Fukuzawa N., Seki T. Contemporary Desensitization with Low Dose Rituximab Ensures Kidney Transplant Outcome beyond ABO Blood Type Incompatibility:A Comparison between past Regimens in Single Institute Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Harada H, Wada Y, Mitsuke A, Hirose T, Fukuzawa N, Seki T. Contemporary Desensitization with Low Dose Rituximab Ensures Kidney Transplant Outcome beyond ABO Blood Type Incompatibility:A Comparison between past Regimens in Single Institute [abstract]. https://atcmeetingabstracts.com/abstract/contemporary-desensitization-with-low-dose-rituximab-ensures-kidney-transplant-outcome-beyond-abo-blood-type-incompatibilitya-comparison-between-past-regimens-in-single-institute/. Accessed June 3, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences